Quarterly report [Sections 13 or 15(d)]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)

v3.25.3
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]                
Research and development personnel expense $ 1,661,646     $ 2,287,525     $ 5,696,691 $ 5,556,694
General and administrative personnel expense 1,827,197     1,137,328     4,589,925 3,759,781
Total 3,436,573 $ 3,933,918 $ 2,834,405 3,384,703 $ 3,010,326 $ 2,726,381 10,204,896 9,121,410
Reportable Segment, Aggregation before Other Operating Segment [Member]                
Segment Reporting Information [Line Items]                
Preclinical, clinical trial and other costs 1,204,017     1,850,812     4,543,279 4,143,813
Administrative and facilities expense [1] 972,108     644,184     2,431,946 2,301,840
Other income, net 52,270     40,150     81,720 195,065
Total 3,436,573     3,384,703     10,204,896 9,121,410
Reportable Segment, Aggregation before Other Operating Segment [Member] | Employees [Member]                
Segment Reporting Information [Line Items]                
Research and development personnel expense [2] 457,629     436,713     1,153,412 1,412,881
General and administrative personnel expense [3] $ 855,089     $ 493,144     $ 2,157,979 $ 1,457,941
[1] Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.
[2] Research and development personnel costs include employee stock-based compensation expense of $110,239 and $54,018 for the three months ended September 30, 2025 and 2024, respectively, and $165,572 and $130,722 for the nine months ended September 30, 2025 and 2024, respectively.
[3] General and administrative personnel costs include employee stock-based compensation expense of $192,808 and $53,725 for the three months ended September 30, 2025 and 2024, respectively, and $438,118 and $132,905 for the nine months ended September 30, 2025 and 2024, respectively, and are net of reimbursements received from CorLyst, LLC.